What is the difference between 5-Amino-1MQ and GLP-1 (7-37)?

5-Amino-1MQ: Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms. GLP-1 (7-37): Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is 5-Amino-1MQ administered in research settings?

In research settings, 5-Amino-1MQ is typically administered via the oral route. PeptideBase does not provide dosing or administration instructions.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›5-Amino-1MQ vs GLP-1 (7-37)

Peptide Comparison

5-Amino-1MQ vs GLP-1 (7-37)

Name: 5-Amino-1MQ vs GLP-1 (7-37) — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

5-Amino-1MQ

5-Amino-1-methylquinolinium

Fat LossResearch Only

49 providers listed

Full 5-Amino-1MQ profile →

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Bottom line

GLP-1 (7-37) carries stronger published evidence (RCT, 2 key studies) than 5-Amino-1MQ (Animal, 1); both are research compounds.

Quick Verdict

5-Amino-1MQ

Evidence

Preclinical

GLP-1 (7-37)

Evidence

Emerging Clinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	GLP-1 (7-37)
Oral administration option	5-Amino-1MQ
More provider options (49 vs 33)	5-Amino-1MQ

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

5-Amino-1MQ

GLP-1 (7-37)

Mechanism Family

Metabolic

Half-life

—

FDA Status

unknown

not evaluated

Admin Routes

oral

subcutaneous, intravenous

Availability

Research Only

Providers

49 listed

33 listed

Research Evidence

5-Amino-1MQ

PreclinicalAnimal · 1 key study · most recent 2022

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Research Citations

5-Amino-1MQ

Animal2022 · Scientific Reports

NNMT inhibitor in diet-induced obese mice: effects on body weight, body fat, and energy expenditure

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

About 5-Amino-1MQ

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

Research Areas

fat cell reductionmetabolic rateadipose tissue modulation

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

5-Amino-1MQ

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

5-Amino-1MQ

$5.00/mg

$2.88 – $8.00 range

20 vendors

View price index →Find providers →

GLP-1 (7-37)

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

5-Amino-1MQ

49 listed

Browse directory →

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). 5-Amino-1MQ vs GLP-1 (7-37) — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/5-amino-1mq/glp-1-7-37

https://peptidebase.io/peptides/compare/5-amino-1mq/glp-1-7-37 Methodology License Download JSON Download CSV